La Universal Research Center, Inc

Los Angeles, California 90057

3 studies enrolling now · 25 studies all time

What they study most

Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp, COVID-19, Chronic Spontaneous Urticaria, Diabetes, Eczema, Infectious Disease, NonSegmental Vitiligo, Pruritus, RSV Infection, Respiratory Syncytial Virus Infections

Studies at this site

• A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo — Recruiting now
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Enrolling by invitation
• Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection — Stopped early
• Phase 2 Trial of HY209gel in Atopic Dermatitis Patients — Completed
• Efficacy and Safety Study of Moxidectin in Adults With Scabies — Completed
• A Study of Barzolvolimab in Patients With Atopic Dermatitis — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — Completed
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Eversense® Non-adjunctive Use Post Approval Study — Running, not enrolling
• Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) — Completed
• B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis — Completed
• Study of Obeldesivir in Nonhospitalized Participants With COVID-19 — Completed
• A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 — Completed
• A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis — Completed
• Oral Nutritional Supplementation in Children at Risk of Undernutrition — Completed
• Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis — Stopped early
• Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed
• A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis — Stopped early